Apellis Pharmaceuticals Analyst Ratings
Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $43
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $39
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Apellis Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Evaluating Market Dynamics and Physician Preferences: Hold Rating on Apellis Pharmaceuticals Amid Syfovre and Izervay Competition
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Apellis Pharmaceuticals Analyst Ratings
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan